Related content

Targeting hypoxia-inducible factor-2α enhances sorafenib antitumor activity via β-catenin/C-Myc-dependent pathways in hepatocellular carcinoma

By                

Oncology Letters, Vol. 10, Iss. 2, 2015-01 ,pp. : 778-784

Spandidos Publications

Access to resources Recommend Favorite

Silencing ADAM10 inhibits the in vitro and in vivo growth of hepatocellular carcinoma cancer cells

By  

Molecular Medicine Reports, Vol. 11, Iss. 1, 2015-01 ,pp. : 597-602

Spandidos Publications

Access to resources Recommend Favorite

Synergistic effects of co-expression plasmidbased ADAM10-specific siRNA and GRIM-19 on hepatocellular carcinoma in vitro and in vivo

By  

Oncology Reports, Vol. 32, Iss. 6, 2014-01 ,pp. : 2501-2510

Spandidos Publications

Access to resources Recommend Favorite

Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo

By  

Oncology Reports, Vol. 33, Iss. 3, 2015-01 ,pp. : 1551-1559

Spandidos Publications

Access to resources Recommend Favorite

Aspirin enhances doxorubicin-induced apoptosis and reduces tumor growth in human hepatocellular carcinoma cells in vitro and in vivo

By                      

International Journal of Oncology, Vol. 40, Iss. 5, 2012-01 ,pp. : 1636-1642

Spandidos Publications

Access to resources Recommend Favorite